Business
Labaton Keller Sucharow LLP Files Securities Class Action Against Zoetis, Inc. and Certain of Its Executives
Labaton Keller Sucharow LLP Files Securities Class Action Against Zoetis, Inc. and Certain of Its
About this update from Zoetis Inc.
Labaton Keller Sucharow LLP (“Labaton”) has filed a securities class action lawsuit (the “Action”) on behalf of its client the City of Ann Arbor Retiree Health Care Benefit Plan & Trust (“Ann Arbor RHC”) against Zoetis, Inc. (“Zoetis” or the “Company”) (NYSE: ZTS) and certain of its executives (collectively, “Defendants”). The Action, which is captioned City of Ann Arbor Retiree Health Care Benefit Plan & Trust v. Zoetis, Inc., No. 26-cv-04401 (S.D.N.Y.), asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and U.S. Securities and Exchange Commission Rule 10b-5 promulgated thereunder on behalf of all persons and entities that purchased or otherwise acquired Zoetis securities between January 14, 2025 and May 6, 2026, inclusive (the “Class Period”).Zoetis is an animal health company that develops, manufactures, and sells vaccines, medicines, diagnostics, biopharmaceuticals, and digital solutions for companion animals and livestock. Zoetis’ Companion Animal products for dogs and cats are its most important line of business and its principal growth engine.The Action alleges that, throughout the Class Period, Defendants made materially false and misleading statements concerning the growth, competitive positioning, market share, and veterinarian adoption of key products within the Companion Animal segment while failing to disclose that: (i) veterinarian prescription growth and adoption of Zoetis’ Librela, a canine pain treatment, were sharply weakening as clinicians became more cautious following FDA safety warnings concerning serious neurological complications in dogs; (ii) Zoetis’ Simparica Trio was losing significant market share to a lower priced competing canine parasiticide with broader indicated use in a slowing overall market; and (iii) Zoetis’ dermatology products, Apoquel and Cytopoint, were losing substantial market share to a newly launched competing canine treatment.The market began to learn the truth about Defendants’ fraud through a series of disclosures beginning in August 2025 that revealed weakening demand trends, slowing veterinarian adoption, intensifying competitive pressures, and declining growth across Zoetis’ key Companion Animal franchises. Over the following months, additional disclosures further revealed the extent of the deterioration affecting the Company’s core growth products, culminating on...